e-learning
resources
ERJ
2017
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Doxycycline improves clinical outcomes during cystic fibrosis exacerbations
Xin Xu, Tarek Abdalla, Preston E. Bratcher, Patricia L. Jackson, Gina Sabbatini, J. Michael Wells, Xiang-Yang Lou, Rebecca Quinn, J. Edwin Blalock, J. P. Clancy, Amit Gaggar
Source:
Eur Respir J , 49 (4) 1601102; DOI: 10.1183/13993003.01102-2016
Journal Issue:
April
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Xin Xu, Tarek Abdalla, Preston E. Bratcher, Patricia L. Jackson, Gina Sabbatini, J. Michael Wells, Xiang-Yang Lou, Rebecca Quinn, J. Edwin Blalock, J. P. Clancy, Amit Gaggar. Doxycycline improves clinical outcomes during cystic fibrosis exacerbations. Eur Respir J , 49 (4) 1601102; DOI: 10.1183/13993003.01102-2016
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Cystic fibrosis and intestinal organoids
Clinics of Cystic Fibrosis Patients with Unusual Bacteria Isolated fromRespiratory Cultures
Novel therapeutics for cystic fibrosis
Related content which might interest you:
Differences in clinical features and biomarkers of subsequent acute cystic fibrosis pulmonary exacerbations - Analysing exacerbations as separate entities
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults
Year: 2013
Predictive factors for severe pulmonary exacerbations in patients with cystic fibrosis
Source: Eur Respir J 2006; 28: Suppl. 50, 715s
Year: 2006
Effects of long-term azithromycin treatment in patients with non-cystic fibrosis stable bronchiectasis
Source: Annual Congress 2007 - Infectious lung and pleural diseases
Year: 2007
Assessing response to treatment of exacerbations of bronchiectasis in adults
Source: Eur Respir J 2009; 33: 312-318
Year: 2009
Etiology and clinical outcome of pediatric non-cystic fibrosis bronchiectasis
Source: Annual Congress 2010 - Paediatric epidemiology: infection, prematurity and congenital abnormalities
Year: 2010
Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis
Source: Eur Respir J, 54 (6) 1901188; 10.1183/13993003.01188-2019
Year: 2019
Early detection of pulmonary exacerbations in children with cystic fibrosis by electronic home monitoring of symptoms and lung function
Source: International Congress 2016 – Cystic fibrosis: monitoring and management
Year: 2016
The concept of cystic fibrosis pulmonary exacerbation in clinical medicine and as a trial end-point
Source: Annual Congress 2008 - Exacerbations of chronic respiratory disease – state of the art
Year: 2008
Incidence and resource utilisation of pulmonary exacerbations in patients with cystic fibrosis in the UK
Source: Annual Congress 2010 - New aspects of cystic fibrosis
Year: 2010
Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis
Source: Virtual Congress 2021 – Interstitial lung disease around the world
Year: 2021
Exacerbations in non cystic fibrosis bronchiectasis: clinical features and investigations
Source: Annual Congress 2009 - Bacterial infections of upper and lower respiratory tract in childhood
Year: 2009
Efficacy and safety of oral sildenafil in cystic fibrosis childrenwith mild to moderate lung disease
Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis
Year: 2020
Long-term outcomes and clinical worsening in cystic fibrosis patients with at least one residual function mutation
Source: International Congress 2018 – Cystic fibrosis in adults: current research
Year: 2018
Factors associated with recurrence of severe exacerbations in Non-cystic fibrosis bronchiectasis in developping countries.
Source: International Congress 2019 – Clinical problems
Year: 2019
Lung clearance index improves with treatment of an exacerbation in cystic fibrosis
Source: Annual Congress 2007 - Cystic fibrosis lung disease: from diagnosis to end-stage
Year: 2007
Frequent outpatient exacerbations of non cystic fibrosis bronchiectasis leads to impaired health related quality of life
Source: Annual Congress 2007 - Different aspects of COPD exacerbations
Year: 2007
Improvement in pulmonary function after IV antibiotic treatment in cystic fibrosis patients
Source: Eur Respir J 2002; 20: Suppl. 38, 342s
Year: 2002
Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis
Source: Eur Respir Rev 2015; 24: 58-64
Year: 2015
The treatment burden of cystic fibrosis: a day-to-day experience with treatment as someone with cystic fibrosis
Source: Breathe, 17 (1) 210013; 10.1183/20734735.0013-2021
Year: 2021
Inflammatory markers can predict pulmonary exacerbations of cystic fibrosis
Source: International Congress 2017 – Cystic fibrosis: monitoring and biomarkers
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept